Commodore Capital LP Allakos Inc. Transaction History

Commodore Capital LP

4 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2023 May 15, 2023	BUY	$4.3 - $8.27 $1.1 Million - $2.12 Million	256,500 Added 15.61%	1,900,000 $8.46 Million
Q3 2022 Nov 14, 2022	BUY	$3.02 - $6.12 $4.96 Million - $10.1 Million	1,643,500 New	1,643,500 $10.1 Million
Q1 2022 May 16, 2022	SELL	$5.08 - $9.81 $4.14 Million - $8 Million	-815,667 Closed	0 $0
Q4 2021 Feb 14, 2022	BUY	$8.55 - $111.89 $6.97 Million - $91.3 Million	815,667 New	815,667 $7.99 Million

64.7M

47.1K

Ticker ALLK
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 84,726,096
Market Cap $89.8M
Description
Allakos Inc., a clinical stage biopharmaceutical company, develops therapeutics that target immunomodulatory receptors present on immune effector cells in allergy, inflammatory, and proliferative diseases. The company's lead monoclonal antibody is lirentelimab (AK002), which is in a Phase III study for the treatment of eosinophilic gastritis and...

Get notified when there are updates to the investment portfolio of Commodore Capital LP, based on Form 13F filings with the SEC.

Stay updated on Commodore Capital LP with notifications on news.